S57 Identification of Two Upregulated Genes in Tumor Tissues With Poor Prognosis in Pancreatic Ductal Adenocarcinoma via Bioinformatical Analysis

Abstract Objective: Pancreatic ductal adenocarcinoma (PDAC) serves as a prevailing tumor type with high mortality and poor prognosis. The study aims to explore the mechanism of gemcitabine resistance in PDAC patients. Methods: Immunohistochemistry(IHC)was used to analyze the expression of SLC39A1 in PDAC samples. PDAC cells were culture and transfected with siSLC39A1 and siNC, respectively. Cell proliferation analysis was performed using CCK-8 assay. And qPCR and Western blotting was used to analysis the expression level of SLC39A1 and related signal molecular in cells. Results: IHC results demonstrated that the SLC39A1 expression was significantly up-regulated in the gemcitabine-resistant PDAC samples compared with gemcitabine-sensitive PDAC samples. The treatment of gemcitabine dose-dependently inhibited the viability of the PDAC cells. Meanwhile, the mRNA and protein expression of SLC39A1 were elevated in the gemcitabine-resistant PDAC. The treatment of gemcitabine remarkably decreased viability of PDACs, in which SLC39A1 depletion could reverse this effect. SLC39A1 knockdown could reverse the gemcitabine-induced phosphorylation of AMPK enhanced and gemcitabine-inhibited S6K expression. Conclusion: SLC39A1 contributed to gemcitabine resistance of PDAC by activating AMPK signaling.

Download Full-text

Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis

Pancreatology ◽

10.1016/j.pan.2019.03.001 ◽

2019 ◽

Vol 19 (3) ◽

pp. 443-448 ◽

Cited By ~ 3

Author(s):

Yuki Hashimoto ◽

Mitsuaki Ishida ◽

Hironori Ryota ◽

Tomohisa Yamamoto ◽

Hisashi Kosaka ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Poor Prognosis ◽

Immunohistochemical Analysis ◽

Ductal Adenocarcinoma

Download Full-text

Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma

British Journal of Cancer ◽

10.1038/s41416-020-0863-1 ◽

2020 ◽

Vol 123 (1) ◽

pp. 72-80

Author(s):

Fabien Robin ◽

Gaëlle Angenard ◽

Luis Cano ◽

Laetitia Courtin-Tanguy ◽

Elodie Gaignard ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Poor Prognosis ◽

Molecular Profiling ◽

Ductal Adenocarcinoma

Download Full-text

High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma

Journal of Cancer ◽

10.7150/jca.39800 ◽

2020 ◽

Vol 11 (8) ◽

pp. 2213-2221

Author(s):

Ming Cui ◽

Lei You ◽

Bang Zheng ◽

Xinmei Huang ◽

Qiaofei Liu ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Immunoglobulin G ◽

Poor Prognosis ◽

High Expression ◽

Ductal Adenocarcinoma

Download Full-text

Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications

Gastroenterology Research and Practice ◽

10.1155/2014/386561 ◽

2014 ◽

Vol 2014 ◽

pp. 1-11 ◽

Cited By ~ 13

Author(s):

Tao Sun ◽

Xiangyu Kong ◽

Yiqi Du ◽

Zhaoshen Li

Keyword(s):

Pancreatic Cancer ◽

Pancreatic Ductal Adenocarcinoma ◽

Poor Prognosis ◽

Vital Role ◽

High Rate ◽

Ductal Adenocarcinoma ◽

Clinical Implications ◽

Circulating Mirnas ◽

Current Review ◽

Wide Range

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high rate of mortality and poor prognosis. Numerous studies have proved that microRNA (miRNA) may play a vital role in a wide range of malignancies, including PDAC, and dysregulated miRNAs, including circulating miRNAs, are associated with PDAC proliferation, invasion, chemosensitivity, and radiosensitivity, as well as prognosis. Greater understanding of the roles of miRNAs in PDAC could provide insights into this disease and identify potential diagnostic markers and therapeutic targets. The current review focuses on recent advances with respect to the roles of miRNAs in PDAC and their practical value.

Download Full-text